Inhibikase Therapeutics, Inc. (IKT)
Market: NASD |
Currency: USD
Address: 3350 Riverwood Parkway SE
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Show more
📈 Inhibikase Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$8.00
-
Upside/Downside from Analyst Target:
370.59%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.166667 |
- |
2023-06-30 |
- |
Stock split |
|
Total Amount for 2023: $0.166667 |
📅 Earnings & EPS History for Inhibikase Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2026-05-12 (estimated upcoming) | - |
| 2026-03-25 (estimated upcoming) | - |
| 2025-11-12 (estimated upcoming) | - |
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-12 (estimated upcoming) | - |
| 2025-08-11 (estimated upcoming) | - |
| 2025-05-16 | - |
| 2025-05-14 | -0.17 |
| 2025-05-13 | - |
| 2025-05-12 | - |
| 2025-03-27 | -0.5 |
| 2025-03-25 | - |
| 2025-03-24 | - |
| 2024-11-14 | -0.65 |
| 2024-08-14 | -0.66 |
| 2024-08-13 | -0.66 |
| 2024-05-15 | -0.73 |
| 2024-03-27 | -0.64 |
| 2024-03-26 | -0.64 |
| 2023-11-14 | -0.86 |
| 2023-11-13 | -0.86 |
| 2023-08-14 | -1.11 |
| 2023-08-13 | -1.11 |
| 2023-05-15 | -0.16 |
| 2023-05-14 | -0.16 |
| 2023-03-31 | -0.18 |
| 2023-03-30 | -0.18 |
| 2022-11-14 | -0.18 |
| 2022-11-13 | -0.18 |
| 2022-08-12 | -0.18 |
| 2022-08-11 | -0.18 |
| 2022-05-16 | -0.18 |
| 2022-05-15 | -0.18 |
| 2022-03-31 | -0.2 |
| 2022-03-30 | -0.2 |
| 2021-11-15 | -0.18 |
| 2021-11-14 | -0.18 |
| 2021-08-16 | -0.22 |
| 2021-08-15 | -0.22 |
| 2021-05-17 | - |
| 2021-05-16 | - |
| 2021-03-31 | - |
| 2021-03-30 | - |
📰 Related News & Research
No related articles found for "inhibikase therapeutics".
